No Picture
News

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

– Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th- Additional $20 million in cash with an additional future option of $20 million through Oxford loan ame… […]

No Picture
News

Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results

CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that Michael Poirier, President, Chief Executive Officer and Chairman, has issued a letter to Qualigen’s stockholders. The full text is as follows:… […]

No Picture
News

Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates

SAN DIEGO, Nov. 13, 2020 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the firs… […]

No Picture
News

Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cur… […]

No Picture
News

Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results

Recently announced AWARE-1 data further support the potential of pelareorep to induce a durable anti-tumor immune memory effect and improve outcomes in breast cancerInitiated dosing in phase 2 IRENE study evaluating pelareorep-anti-PD-1 combination tre… […]

No Picture
News

Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Launched Phexxi(TM) (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free ContraceptionInitiated Pivotal Phase 3 EVOGUARD Trial of EVO100 for Prevention of Chlamydia and GonorrheaSecured $25 Million Strategic Investment from Adjuvan… […]